GRM5 and major depressive disorder: [11C]ABP688 has previously been used to investigate several psychiatric illnesses and repeated intraindividual measures using [11C]ABP688 have been able to show a reduction in mGluR5 availability following the administration of ketamine in patients with depression and healthy volunteers (DeLorenzo et al., 2015; Esterlis et al., 2018).